In previous studies we showed that 5 days of treatment with granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) mobilized murine repopulating cells into the peripheral blood (PB) and that these cells could be efficiently transduced with retroviral vectors. We also found that, 7-14 days after cytokine treatment, the repopulating ability of murine bone marrow (BM) increased 10-fold. In Despite promising results with murine and in vitro models, retroviral gene transfer into human long-term repopulating hematopoietic stem cells (HSCs) has been too inefficient to expect that clinical benefit will result (1). Many transduction conditions have been tested, including the inclusion ofvarious hematopoietic cytokines, coculture on stromal cell populations, and the use of physical methods to increase the likelihood of target cell-vector interaction (2-6). These methods have been successful at improving gene transfer efficiency into committed human progenitor cells assayed in vitro, but in primate transplantation models and in early human clinical studies approximately 1% or less of circulating hematopoietic cells contained the transferred gene (7-11).
7-14 days after cytokine treatment, the repopulating ability of murine bone marrow (BM) increased 10-fold. In this study we examined the efficiency of gene transfer into cytokine-primed murine BM cells and extended our observations to a nonhuman primate autologous transplantation model. G-CSF/SCF-primed murine BM cells collected 7-14 days after cytokine treatment were equivalent to post-5-fluorouracil BM or G-CSF/SCFmobilized PB cells as targets for retroviral gene transfer. In nonhuman primates, CD34-enriched PB cells collected after 5 days of G-CSF/SCF treatment and CD34-enriched BM cells collected 14 days later were superior targets for retroviral gene transfer. When a clinically approved supernatant infection protocol with low-titer vector preparations was used, monkeys had up to 5% of circulating cells containing the vector for up to a year after transplantation. This relatively high level of gene transfer was confirmed by Southern blot analysis. Engraftment after transplantation using primed BM cells was more rapid than that using steady-state bone marrow, and the fraction of BM cells having the most primitive CD34+/CD38-or CD34+/CD38dim phenotype increased 3-fold. We conclude that cytokine priming with G-CSF/SCF may allow collection of increased numbers of primitive cells from both the PB and BM that have improved susceptibility to retroviral transduction, with many potential applications in hematopoietic stem cell-directed gene therapy.
Despite promising results with murine and in vitro models, retroviral gene transfer into human long-term repopulating hematopoietic stem cells (HSCs) has been too inefficient to expect that clinical benefit will result (1) . Many transduction conditions have been tested, including the inclusion ofvarious hematopoietic cytokines, coculture on stromal cell populations, and the use of physical methods to increase the likelihood of target cell-vector interaction (2) (3) (4) (5) (6) . These methods have been successful at improving gene transfer efficiency into committed human progenitor cells assayed in vitro, but in primate transplantation models and in early human clinical studies approximately 1% or less of circulating hematopoietic cells contained the transferred gene (7) (8) (9) (10) (11) .
In vivo manipulation of HSCs prior to cell harvesting and transduction may improve retroviral gene transfer into HSCs by promoting cell cycling or increasing receptor density. In the murine model, the successful prototype of this approach is the administration of 5-fluorouracil (5-FU) to mice 2-4 days prior to harvesting of bone marrow (BM) (12, 13) . In our rhesus model, we have seen similar gene transfer efficiencies with or without the preharvest use of 5-FU (10, 14) . The best results to date in human clinical trials were reported when BM cells for transduction were harvested from children soon after treatment with very high-dose chemotherapy, perhaps due to increased cycling of primitive populations during the regenerative phase (15) . Pretreatment of humans with 5-FU at tolerated doses has not produced efficient gene transfer to repopulating cells, and very high-dose antileukemic chemotherapy is not practical or safe in patients with congenital deficiency disorders, human immunodeficiency virus infection, or other candidate diseases for HSC gene therapy (7) .
Hematopoietic cytokines have been shown to mobilize large numbers of primitive hematopoietic cells into the peripheral blood (PB) of mice, primates, and humans (16) . These cells have sustained repopulating ability in the murine model, and have been successfully used as a source of long-term repopulating cells in human autologous and allogeneic transplantation (17, 18) . The combination of stem cell factor (SCF) and granulocyte colonystimulating factor (G-CSF) is the most effective combination described for mobilizing primitive cells into the blood. We have previously shown in the murine model that SCF/G-CSFmobilized PB cells are excellent targets for retroviral gene transfer, with long-term marking efficiencies equivalent or better than 5-FU-primed BM (19) . More recently we showed that the repopulating ability of BM from mice treated with SCF/G-CSF for 5 days was transiently increased up to 15-fold 10-18 days after cessation of the cytokine treatment, suggesting an in vivo expansion of stem cell numbers triggered by this perturbation (20 Table 3 shows the cell numbers collected, the degree of progenitor enrichment resulting from CD34 selection, the cell numbers present at the end of transduction, and the estimated transduction efficiency of the CD34-enriched population at the end of transduction. All animals received over 10 million total CD34-enriched and cultured cells per kilogram. Both PB and BM cells were reinfused after total body irradiation. The two animals recovered granulocyte counts to greater than 500/,ul on days 10 and 14, respectively, faster than rhesus monkeys in our previous studies transplanted with CD34-enriched steady-state BM that engrafted on days 18-24 (14) . The animals were followed for the presence and the origin of the neo gene after engraftment. Fig. IA shows semiquantitative PCR analyses at short-and long-term intervals after transplantation. Mononuclear *Marrow non-fat-cellularity estimate based on a trephine biopsy sample taken from iliac crest.
Medical Sciences: Dunbar et aL T cells in both animals and B cells in one animal were also positive for the marker gene, at levels of 3-5%. Repeat determinations every 1-2 months on PB and BM samples over a 12-month time period in both animals have given similar results. The LNL6 and GlNa amplification products were separated on a denaturing gel (Fig. IB) . In animal J370, the signal (GlNa) originating from the marked BM graft was initially stronger, but signals from the primed PB (LNL6) and BM (GlNa) grafts have persisted for over 12 months, with approximately 1:1 contributions. Animal 85G has shown a constant pattern of marking from both the primed PB and BM at similar levels over time.
The relatively high level of vector-containing blood cells we observed using semiquantitative PCR was confirmed by Southern blot analysis. Fig. 2 shows that in animal J370, a band hybridizing to a neo probe could be detected after DNA digestion with an enzyme that cuts in the long terminal repeat (LTR) of both vectors, with an intensity corresponding to 4-5%. The band size indicates origin from the GlNa vector, which was used to mark the primed BM. When the samples were cut with a restriction enzyme cutting once within the provirus to study the number of insertion sites, no bands were detectable, suggesting that more than one clone was contributing to the marking (data not shown).
Retroviral Table 3 shows the cell numbers, progenitor enrichment after CD34 selection, and transduction efficiency of the CD34-enriched cells. The animals reached neutrophil counts of 500 per ,l on days 13 and 14, again faster than animals transplanted with steady-state CD34-enriched marrow alone (14) . As shown in Fig. 3B , animal 93B030 had no band from the steady-state BM early after transplant, and at 6 months, the primed BM band remained much stronger. In animal 57G at day 43 after transplantation, only the band corresponding to the primed BM was detected. At later times, both bands were detectable, suggesting a greater effect on cells responsible for repopulation early after transplantation.The overall level of marking in both animals was in the 1-3% range, (Fig. 3A) and it has persisted in this range for over 9 months. Sorted populations of T cells, B cells, and granulocytes were all found to be positive for the neo vectors.
Comparison ofPost-transplantation Levels ofneo Gene Marking as Assessed by Analysis of BM Progenitor Colonies Compared with Mature PB Cells. At 4-12 months post-transplantation in all four animals, concurrent samples were taken from the PB and BM. PCR was performed on DNA extracted directly nuclear cells, or total nucleated BM cells containing the neo gene. PB CFU-C were also analyzed 12 months after transplant in two animals. The percentage of colonies containing the neo gene was similar to that found in the BM, and it was considerably higher than the overall copy number in circulating PB cells (data not shown).
eo gene in the DISCUSSION ocytes, monoThe combination of SCF and G-CSF has been shown to be a safe and very efficient regimen for mobilizing primitive hematopoietic Jards-50ng cells into the PB, but the effects on BM have not been extensively investigated (28) (29) (30) (31) (32) . In the murine model, long-term repopulating activity (LTRA) on the 5th day of cytokine treatment had decreased 4-fold, but more recently we reported a marked transient increase in murine BM LTRA 1-2 weeks after cessation of SCF/G-CSF (20 The amphotropic envelope receptor density may increase on the most primitive cells. We are currently investigating these variables. The ex vivo culture viability and engraftment potential of the LTRA is clearly increased in the murine G-CSF/SCF-primed cells, and it may also be improved in the primate. The animals used were young adults; it remains to be seen if improved results would be seen with juvenile animals, analogous to the improved results seen in human children as compared with adults (15) .
The discrepancy between the percentage of marked progenitors present in the marrow after transplantation and the percentage of marked circulating cells was a consistent but puzzling finding in the four rhesus monkeys analyzed in these experiments. This phenomenon has been reported previously in the children with adenosine deaminase-deficient severe combined immunodeficiency that received cord blood cells transduced with a neo-ADA vector. PB populations and whole BM contained only 0.01-0.1% marked cells, but 1% of BM CFU-C or sorted BM CD34+ cells contained the vector (8) . This discrepancy was also seen in one published human gene marking study with neo gene vectors (15) . There are a number of possible explanations, including direct toxicity of the neo gene product phosphotransferase to maturing hematopoietic cells in vivo, immune reactivity against the neo gene product in maturing cells, or differential contribution of various primitive progenitor populations to the CFU-C versus the fully maturing BM cell populations in vivo. The expression of the neo gene has been reported to retard differentiation of the HL60 human leukemic cell line (35) . There is accumulating evidence that immune response against vector-encoded transgenes is a widespread problem (36, 37 
